N2-(1-carboxyethyl)-2'Deoxyguanosine (CEdG) a Potential Biomarker for Diabetes

NACompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

February 11, 2019

Study Completion Date

February 11, 2019

Conditions
Diabetes
Interventions
OTHER

N2-(1-carboxyethyl)-2'deoxyguanosine (CEdG)

"Glucose and its adducts, such as HbA1c, decompose non-enzymatically to yield α-oxo-aldehydes are up to 20,000 x more reactive than the parent molecule. Amounts of an α-oxo-aldehyde, methylglyoxal (MG), are elevated up to 6-fold in patients with Type 1 dm. Quantitation of MG, but MG does form stable, irreversible adducts termed advanced glycation endproducts (AGEs) that can be measured. MG also reacts with DNA to yield primarily one stable DNA-AGE, CEdG, and suggests that measuring CEdG might allow for a direct method for assessing glycemic status and α-oxo-aldehyde burden.~Investigators have shown that CEdG levels are significantly elevated in urine and tissue of Type 1 \& 2 dm animal models. DNA-AGE may correlate with the development of diabetes complications and identify patients at higher risk. Therefore, the investigators hypothesize that CEdG, a DNA-AGE, can be used as a marker of diabetes control and complications."

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
lead

City of Hope Medical Center

OTHER

NCT02065310 - N2-(1-carboxyethyl)-2'Deoxyguanosine (CEdG) a Potential Biomarker for Diabetes | Biotech Hunter | Biotech Hunter